Status:

RECRUITING

White Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease

Lead Sponsor:

IRCCS Policlinico S. Donato

Conditions:

Mild Cognitive Impairment

Alzheimer Disease

Eligibility:

All Genders

65+ years

Brief Summary

This study focuses on assessing and measuring white matter hyperintensities in individuals with amnestic mild cognitive impairment (aMCI) or Alzheimer's disease. Objective: The primary objective of ...

Eligibility Criteria

Inclusion

  • Participants diagnosed with amnestic Mild Cognitive Impairment (aMCI) or Alzheimer's Disease (AD) based on clinical assessments.
  • Individuals undergoing brain magnetic resonance imaging (MRI) at the IRCCS Policlinico San Donato as part of routine diagnostic procedures.
  • Age-matched and gender-matched healthy control subjects for comparison.

Exclusion

  • Individuals with cognitive impairment other than amnestic MCI or AD.
  • History of significant neurological disorders (other than MCI or AD) that may impact the study outcomes.
  • Presence of contraindications for undergoing MRI procedures.
  • Any serious medical or psychiatric condition that, in the judgment of the researchers, may interfere with the study participation or compromise the validity of the results.
  • Known history of alcohol or substance abuse that may affect cognitive function.
  • Inability or unwillingness to provide informed consent.

Key Trial Info

Start Date :

July 21 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

142 Patients enrolled

Trial Details

Trial ID

NCT06179680

Start Date

July 21 2022

End Date

December 1 2026

Last Update

July 9 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS Policlinico San Donato

San Donato Milanese, Milano, Italy, 20097